SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced that senior management will participate in TD Cowen 45th Annual Health Care Conference and Leerink Partners Global Healthcare Conference 2025. Members of Alterome management will participate in one-on-one investor meetings at both conferences. Details of participation are as follows:
TD Cowen 45th Annual Health Care Conference
Date: March 3
Location: Boston, MA
Leerink Partners Global Healthcare Conference 2025
Date: March 10
Location: Miami, FL
About Alterome Therapeutics, Inc.
Alterome Therapeutics, Inc. is a clinical-stage precision oncology biotechnology company developing alteration-specific therapeutics to address high-value and validated oncogenic drivers. Our pipeline includes two Phase 1 therapies in development for solid tumors: ALTA2618, a first-in-class, oral mutation-selective inhibitor for AKT1 E17K-driven cancers, and ALTA3263, a best-in-class, oral pan-KRAS isoform-selective inhibitor for KRAS-driven cancers. Alterome has raised more than $231 million in venture capital to date and is led by a team of precision oncology R&D leaders with a history of developing marketed oncology small molecule drugs.
For more information, visit www.alterome.com and follow us on LinkedIn.
Contacts
Investors:
Scott Moorefield
Alterome Therapeutics
investors@alterome.com
Media:
Michael Galfetti
Ten Bridge Communications
Alterome@tenbridgecommunications.com
